7.735  -0.135 (-1.72%)		01-09 16:00
Open: 7.99 High: 8.22 Volume: 33,506		Pre. Close: 7.87 Low: 7.51 Market Cap: 72(M)

Short term
Mid term
Targets	6-month :	9.9	1-year :	10.76
Resists	First :	8.48	Second :	9.22
Pivot price	7.93
Supports	First :	7.28	Second :	6.06
MAs	MA(5) :	7.78	MA(20) :	8.01
	MA(100) :	8.31	MA(250) :	7.41
MACD	MACD :	-0.2	Signal :	-0.2
%K %D	K(14,3) :	44.5	D(3) :	40.6
RSI	RSI(14): 44.3
52-week	High :	16.94	Low :	1.91

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CRVO ] has closed above bottom band by 30.3%. Bollinger Bands are 48.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	8.23 - 8.28	8.28 - 8.32
Low:	7.4 - 7.46	7.46 - 7.5
Close:	7.65 - 7.74	7.74 - 7.81

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

Thu, 18 Dec 2025
Cantor Fitzgerald Initiates Coverage on CervoMed (CRVO) with Ove - GuruFocus

Thu, 04 Dec 2025
CervoMed (NASDAQ: CRVO) Phase 2b shows 75% drop in DLB progression risk, eyes Phase 3 - Stock Titan

Wed, 19 Nov 2025
CervoMed Inc.: Chief commercial officer Winton buys $41k in CRVO - Investing.com

Wed, 19 Nov 2025
Is CervoMed (NASDAQ:CRVO) In A Good Position To Invest In Growth? - simplywall.st

Wed, 19 Nov 2025
CervoMed Inc. Stock (CRVO) Opinions on Insider Buying and Clinical Trial Progress | CRVO Stock News - Quiver Quantitative

Thu, 13 Nov 2025
Elder William, CervoMed CFO, buys $26k in CRVO stock - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	9 (M)
Held by Insiders	5.42e+006 (%)
Held by Institutions	32.1 (%)
Shares Short	111 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-2 %
Return on Assets (ttm)	493.7 %
Return on Equity (ttm)	-42.8 %
Qtrly Rev. Growth	6.16e+006 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	-3 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-25 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-17.84

Dividend	0
Forward Dividend	153810
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.